GSTO2 and amyotrophic lateral sclerosis: In addition, GST downregulation was already reported in ALS patients [80], while GSTO-2 overexpression in a Drosophila model of ALS recovered defective phenotypes, supporting the hypothesis that it represents a potential therapeutic target for ALS [81].